For research use only. Not for therapeutic Use.
Afelimomab（Cat No.:I042182）is a monoclonal antibody that targets and inhibits the tumor necrosis factor-alpha (TNF-α) receptor. TNF-α is a pro-inflammatory cytokine involved in immune responses and inflammation, and its overproduction is associated with various inflammatory and autoimmune diseases. By blocking the TNF-α receptor, afelimomab aims to reduce inflammation and modulate immune activity, potentially providing therapeutic benefits in conditions like rheumatoid arthritis, Crohn’s disease, and other inflammatory disorders. It is being studied in clinical trials to assess its safety, efficacy, and potential as a treatment for chronic inflammatory diseases.
| Catalog Number | I042182 |
| CAS Number | 156227-98-4 |
| Purity | ≥95% |
